Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Eshaghi B, Wang EY, Mursalova S, Forster TA, Lasrado N, Tian J, Artzi D, Lin SQ, Wu Z, Yang X, Chung W, Sadeghi I, Garcia J, Chen Z, Sheridan O, Das R, Lau A, Gurram A, Mainou BA, Jones KAV, Liu Y, Barouch DH, von Andrian U, Langer R, Jaklenec A. Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine. Sci Adv. 2026 Jun 05; 12(23):eaea5433.
-
Steinbuck MP, Seenappa LM, Zhan W, Palmer E, Jung MM, Jakubowski A, Cabana-Puig X, McNeil LK, Haqq CM, Fitzgerald KA, DeMuth PC. Lymph node-targeted DNA engages TBK1/IFN-I-driven innate immunity to induce potent T cell responses and durable memory in mice and NHPs. Sci Adv. 2026 May 29; 12(22):eaec1416.
-
Korn P, Pallauf M, Herrera-Caceres JO, Lokeshwar S, Essien M, Small A, Raskolnikov D, Kleinmann N, Shvero A, Matin SF, Labbate C, Kaimakliotis H, Tachibana I, Linehan J, Choe J, Shah O, Movassaghi M, Huang W, Persily J, Perecman A, Canes D, Pessoa RR, Potretzke A, Raman JD, Singla N. Patterns of adjuvant intracavitary instillation and recurrence after endoscopic management of upper tract urothelial carcinoma. World J Urol. 2026 May 19; 44(1).
-
Kane GI, Naylor TE, Lusi EF, Brassil ML, Wigglesworth K, Dinnell RW, Diaz-Infante MB, Whiteman LM, Lukas J, Winkler M, Josh R, Cerrutti J, Mori H, Gallucci S, Fitzgerald KA, Atukorale PU. Super-adjuvant nanoparticles for platform cancer vaccination. Cell Rep Med. 2025 Oct 21; 6(10):102415.
-
Almeida GG, Pinto JA, Pinto PM, da Silva LB, Andrade LAF, Valiate BVS, Zini N, Bagno FF, Rivelli GG, Louren?o KL, Souza JPC, Gomes IP, de Castro NS, Maia ALC, de Carvalho AF, Alves JC, de Castro JT, Li G, da Rocha Fernandes G, Alves PA, Diniz RC, Daher AB, de Souza RP, Teixeira SMR, Fernandes APSM, Gazzinelli RT, da Costa Santiago H. Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19. Vaccine. 2025 Oct 03; 64:127756.
-
Vadovics M, Zhao W, Daley EF, Lam K, Daly O, Rashid K, Lee HR, Schreiner P, Lundgreen KA, Gaudette BT, Shuvaev VV, Arguiri E, Muramatsu H, S?rk?zy A, Mdluli T, Xu J, Han X, De Luna N, Casta?o D, Bettini E, ?brah?m E, Lipinszki Z, Carlucci G, Bansode AH, Nguyen K, Le TM, Luu T, Muzykantov VR, Bates P, Allman D, Mitchell MJ, Locci M, Radu CG, Heyes J, Pardi N. Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications. Nat Nanotechnol. 2025 Sep; 20(9):1312-1322.
-
Violari A, Otwombe K, Hahn W, Chen S, Josipovic D, Baba V, Angelidou A, Smolen KK, Levy O, Mkhize NN, Woodward Davis AS, Martin TM, Haynes BF, Williams WB, Sagawa ZK, Kublin JG, Polakowski L, Brewinski Isaacs M, Yen C, Tomaras G, Corey L, Janes H, Gray GE. Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns. J Clin Invest. 2025 Jun 02; 135(11).
-
Wang R, Oliveira LVN, Hester MM, Carlson D, Christensen D, Specht CA, Levitz SM. Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines. PLoS Pathog. 2024 Jul; 20(7):e1012220.
-
Alsaiari SK, Nadeef S, Daristotle JL, Rothwell W, Du B, Garcia J, Zhang L, Sarmadi M, Forster TA, Menon N, Lin SQ, Tostanoski LH, Hachmann N, Wang EY, Ventura JD, Barouch DH, Langer R, Jaklenec A. Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer. Sci Adv. 2024 03 08; 10(10):eadj6380.
-
Marques RF, Gimenez AM, Caballero O, Simpson A, Salazar AM, Amino R, Godin S, Gazzinelli RT, Soares IS. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol?) as adjuvant. Vaccine. 2024 04 02; 42(9):2394-2406.